Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China ,...
Biocytogen Pharmaceuticals
Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment
Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have...
Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...
Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody...
Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced...
Biocytogen Pharmaceuticals Enters Agreement with Myricx Bio for ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody evaluation, option, and...
Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...
Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations...
Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a...
Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...
Biocytogen Pharmaceuticals Receives CNIPA Patent for RenMab Human Antibody Mice Platform
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...
Biocytogen and Hansoh Enter Antibody Collaboration and Licensing Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license...
Biocytogen and ADC Therapeutics Enter Evaluation and Option Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an evaluation and option agreement with Swiss...
Biocytogen Announces Successful Development of Fully-Human Nano Antibody RenNano
Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano...
Eucure Biopharma Partners with ISU ABXIS to Develop Tri-Specific Antibodies Using YH003
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...